To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer.
Status:
Withdrawn
Trial end date:
2021-11-04
Target enrollment:
Participant gender:
Summary
This study will recruit 168 patients in approximately 20 study centres in China.
The primary objective of this study is to examine whether ZOLADEX 10.8 mg depot is
non-inferior to ZOLADEX 3.6 mg depot in terms of the suppression rate of serum estradiol (E2)
to the menopausal level (≤30 pg/mL) from Week 4 through Week 24.